ANGANY CEO Louis-Philippe Vézina is pleased to announce the nomination of Pr. Ronald van Ree PhD, as chairperson of ANGANY’s Scientific Advisory Board. Pr. Van Ree heads the Laboratory for…
News
Lévis, QC. – Built by Mecart Inc. of St-Augustin-de-Desmaures, QC during the challenging context of a pandemic, this production and analytic suite greatly adds to ANGANY’s operational capabilities and will…
Dr. Carrier brings over 20 years of management experience in the pharmaceutical industry with a history of success in developing, submitting and approving multiple drug applications in Canada, United States…
ANGANY has contracted the installation of a manufacturing pilot unit in clean rooms. This will provide a capacity to manufacture clinical batches in GMP conditions for Phase I and Phase…
A Franco-Canadian start-up is tackling allergic dermatitis delivery with immunotherapy treatments produced by plants. Animalpharm
Reims, France. – In her invited presentation Dr. Gomord reviewed new avenues in allergy immunotherapy. http://ciaballergie.org/
Orlando, FL. -High level executive exchanges were held with select veterinary pharmaceutical companies from around the world, particularly with regards to ANGANY’s canine atopic dermatitis (CAD) products under development. https://navc.com/vmx/
Canadian pharma start-up enlists LEVOYA to move further into animal health. Animalpharm
Ventura, CA. – Pr. Ronald van Ree and Dr. Guy Tropper presented a scientific poster on behalf of ANGANY’s team and several collaborators at this prestigious, invitation-only scientific meeting gathering…
San Francisco, CA. – ANGANY delegates attended this conference on the latest developments in vaccines and immunotherapy. ANGANY held a presentation titled: “Bioparticle-Potentiated Immunotherapy: Introducing a new bioparticle platform /…